ABLYNX (OTCMKTS:ABLYF) will be announcing its earnings results after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.
ABLYNX (OTCMKTS:ABLYF) opened at $52.00 on Wednesday. ABLYNX has a one year low of $11.10 and a one year high of $54.75.
Several equities analysts recently issued reports on ABLYF shares. Zacks Investment Research upgraded ABLYNX from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Monday, January 8th. Bank of America started coverage on ABLYNX in a research note on Friday, November 10th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, ValuEngine upgraded ABLYNX from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.